title: The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.
abstract: Cannabis use has been reported to increase the risk of developing schizophrenia and to worsen symptoms of the illness. Both of these outcomes might be attributable to the disruption by cannabis of the endogenous cannabinoid system's spatiotemporal regulation of the inhibitory circuitry in the prefrontal cortex that is essential for core cognitive processes, such as working memory, which are impaired in schizophrenia. In the healthy brain, the endocannabinoid 2-arachidonylglycerol 1) is synthesized by diacylglycerol lipase in pyramidal neurons; 2) travels retrogradely to nearby inhibitory axon terminals that express the primary type 1 cannabinoid receptor (CB1R); 3) binds to CB1R, which inhibits gamma-aminobutyric acid release from the cholecystokinin-containing population of interneurons; and 4) is metabolized by either monoglyceride lipase, which is located in the inhibitory axon terminal, or by α-β-hydrolase domain 6, which is co-localized presynaptically with diacylglycerol lipase. Investigations of the endogenous cannabinoid system in the prefrontal cortex of subjects with schizophrenia have found evidence of higher metabolism of 2-arachidonylglycerol, as well as both greater CB1R receptor binding and lower levels of CB1R messenger RNA and protein. Current views on the potential pathogenesis of these alterations, including disturbances in the development of the endogenous cannabinoid system, are discussed. In addition, how interactions between these alterations in the endocannabinoid system and those in other inhibitory neurons in the prefrontal cortex in subjects with schizophrenia might increase the liability to adverse outcomes with cannabis use is considered.
authors.affiliation: Departments of Psychiatry, Pittsburgh, Pennsylvania. Electronic address: volkdw@upmc.edu.
authors.forename: David W
authors.initials: DW
authors.lastname: Volk
authors.affiliation: Departments of Psychiatry, Pittsburgh, Pennsylvania; Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania.
authors.forename: David A
authors.initials: DA
authors.lastname: Lewis
mesh_terms: D001095:Arachidonic Acids / Q000009:adverse effects* / Q000494:pharmacology; D003071:Cognition; D063388:Endocannabinoids / Q000009:adverse effects* / Q000494:pharmacology; D005989:Glycerides / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D007395:Interneurons / Q000187:drug effects*; D017397:Prefrontal Cortex / Q000503:physiopathology*; D017966:Pyramidal Cells / Q000187:drug effects*; D012333:RNA, Messenger / Q000235:genetics; D043884:Receptor, Cannabinoid, CB1 / Q000235:genetics; D012559:Schizophrenia / Q000503:physiopathology*; D015398:Signal Transduction; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D001095:Arachidonic Acids; D063388:Endocannabinoids; D005989:Glycerides; D012333:RNA, Messenger; D043884:Receptor, Cannabinoid, CB1; D005680:gamma-Aminobutyric Acid; C094503:glyceryl 2-arachidonate
keywords: CB(1)R; Cannabinoid; Cannabis; Cognitive; Inhibitory; Prefrontal cortex